Eyes On Trials

  ABC Pharmaceuticals, a pioneering biotech firm known for its cutting-edge research in therapeutic innovations. Amidst their quest for groundbreaking treatments, they encountered a pivotal juncture during a Phase IIb/III cardiovascular trial. Regulatory shifts, supply chain vulnerabilities, and safety concerns cast a shadow over their aspirations. This is the story of how the Clinical Project Manager, redefined risk management, embracing challenges as catalysts for innovation while transforming stakeholder conversations. ABC Pharmaceuticals, driven by innovation, harbored a risk-averse culture—prioritizing safety and efficacy without aggressively embracing uncertainties. CPM recognized the need for a paradigm shift. He envisioned risk not merely as a hurdle but as a potential driver of transformative change within the trial landscape. The Evolution of Risk Management: Identifying the Challenges: ABC Pharmaceuticals’ initial risk assessments identified potential disruptions:...

Risk Analysis in Clinical Trials-Overview   What Is Risk Analysis? Risk Analysis is the process of determining the significance of risks. The result of the risk evaluation technique is an update to our risk register showing the priorities of the risks. Using risk thresholds to determine which risks are urgent and require treatment. There are many ways to analyze risks. We can simply assign a Low, Medium, or High rating for each risk.   A better method is to evaluate the probability (likelihood) and impact (consequence) of each risk, assigning a numeric rating such as 1 to 5, 5 being the highest. When to Evaluate Risks Should start evaluating risks early in their projects; should continue evaluating risks in an iterative until the project is completed. Importance: Inspection cost us money, but what are our risks without the inspection? A few years later. Imagine the inconvenience, the amount of time, and the cost to replace the data/things. There is alwa...